US 12,433,491 B2
Treatment device having multifunctional sensing elements and method of use
Boaz Avitall, Chicago, IL (US)
Assigned to Medtronic CryoCath LP, Toronto (CA)
Filed by Medtronic CryoCath LP, Toronto (CA)
Filed on Nov. 21, 2022, as Appl. No. 18/057,621.
Application 18/057,621 is a division of application No. 15/499,036, filed on Apr. 27, 2017, granted, now 11,510,576.
Prior Publication US 2023/0095567 A1, Mar. 30, 2023
Int. Cl. A61B 18/14 (2006.01); A61B 5/00 (2006.01); A61B 5/01 (2006.01); A61B 5/053 (2021.01); A61B 5/0536 (2021.01); A61B 5/0538 (2021.01); A61B 5/283 (2021.01); A61B 5/287 (2021.01); A61B 18/02 (2006.01); A61B 18/00 (2006.01)
CPC A61B 5/01 (2013.01) [A61B 5/053 (2013.01); A61B 5/0536 (2013.01); A61B 5/0538 (2013.01); A61B 5/283 (2021.01); A61B 5/287 (2021.01); A61B 5/6853 (2013.01); A61B 18/02 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00357 (2013.01); A61B 2018/00375 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00797 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/00863 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/0262 (2013.01); A61B 2505/05 (2013.01); A61B 2562/046 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of determining lesion transmurality, the method comprising:
positioning a treatment element of a medical device in contact with an area of tissue, the treatment device being in fluid communication with a source of cryogenic fluid and including a cryoballoon, a plurality of mapping electrodes directly coupled to an outer surface of the cryoballoon and positioned to contact the area of tissue, a first plurality of electrodes, and a second plurality of electrodes different than the first plurality of electrodes;
recording, with each of the plurality of mapping electrodes, the first plurality of electrodes, and the second plurality of electrodes, from the area of tissue, at least one of a pre-treatment unipolar impedance measurement, a pre-treatment bipolar impedance measurement, a pre-treatment pace threshold measurement, and a pre-treatment electrogram amplitude;
transmitting, with each of the plurality of mapping electrodes, the first plurality of electrodes, and the second plurality of electrodes, at least one pre-treatment recording to a control unit having processing circuitry;
circulating the cryogenic fluid within the cryoballoon to lower the temperature of the cryoballoon to a temperature that is sufficient to ablate tissue;
ceasing the circulation of the cryogenic fluid within the cryoballoon;
recording, with each of the plurality of mapping electrodes, the first plurality of electrodes, and the second plurality of electrodes, from the area of tissue, at least one of a corresponding post-treatment unipolar impedance measurement, a post-treatment bipolar impedance measurement, a post-treatment pace threshold measurement, and a post-treatment electrogram amplitude;
transmitting, with each of the plurality of mapping electrodes, the first plurality of electrodes, and the second plurality of electrodes, the at least one post-treatment measurement to the control unit;
comparing, with the control unit, the at least one pre-treatment measurement to the at least one post-treatment measurement; and
determining, with the control unit, lesion transmurality in the area of tissue based on the comparison.